BioSpace News Archive

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.

With support from Peter Thiel, Eli Lilly partner AbCellera looks to join the NASDAQ with the biggest Canadian biotech debut on record.

Completion of dedicated CGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS gene therapy product candidates as they advance through clinical trials to commercialization

Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that the U.S. Food and Drug Administration has accepted the filing of a New Drug Application for brincidofovir as a medical countermeasure for smallpox.

OTCQB: PetVivo Holdings, Inc. an emerging biomedical device company operating in the $19B veterinary market announced it will be exhibiting at the American Association of Equine Practitioners Virtual Convention and Trade Show from December 5th to December 8th, 2020 that can be accessed online at https://convention.aaep.org/.

Amicus Therapeutics, a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced that it has been nationally recognized as a Great Place to Work-Certified™ Company in 2020.

GW Pharmaceuticals plc, a world leader in the science, development, and commercialization of cannabinoid prescription medicines, announced that the Company will present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference on Thursday, December 10, 2020 at 11:00am EST.

Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Two Late Breaker and Six e-Poster Presentations, Including Encore of REDUCE-IT® EPA, Primary Results of the VASCEPA COVID-19 CardioLink-9 Trial, and Mechanism of Action Insights

Potential to be the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin

New 5.6 mg Dose Achieved Statistically Significant Pain Reduction Over Placebo at Week 14 (Primary Endpoint, p=0.01)